Cumberland Pharmaceuticals Inc.CPIXNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -9.92% | +11.57% | +37.84% | +10.04% | -8.73% |
| Gross Profit Growth | -6.70% | +8.13% | +48.61% | +8.46% | -5.92% |
| EBITDA Growth | -97.58% | +0.00% | +0.00% | +52.05% | -6190.71% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | -1.57% | -1.36% | +5.99% | +5.97% | +6.41% |
| Weighted Average Shares Diluted Growth | -1.57% | -1.36% | +8.24% | +5.97% | +6.41% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -61.55% | +83.12% | +0.00% | +0.00% | -60.64% |
| Free Cash Flow Growth | -54.77% | +96.96% | +0.00% | +0.00% | -68.35% |
| Receivables Growth | -10.38% | +19.91% | -1.50% | -11.21% | -7.78% |
| Inventory Growth | -47.99% | -13.22% | -5.28% | -25.09% | -34.92% |
| Asset Growth | -12.54% | -7.57% | -14.20% | -13.52% | -14.14% |
| Book Value per Share Growth | -30.05% | -21.73% | -1.64% | +0.25% | -0.94% |
| Debt Growth | +15.20% | +11.63% | -51.77% | -52.06% | -52.34% |
| R&D Expense Growth | -32.14% | +2.21% | +11.81% | +38.63% | -4.04% |
| SG&A Expenses Growth | -0.20% | -7.92% | +2.64% | +1.33% | -0.95% |